Conavi Medical Reports Fiscal Second Quarter 2026 Results and Operational Highlights

Why It Matters

The clearance positions Conavi to capture a growing market for image‑guided coronary interventions, while the financing plan aims to bridge the capital gap needed for a U.S. commercial launch. Success could accelerate adoption of hybrid IVUS‑OCT technology across cardiology practices.

Key Takeaways

• FDA 510(k) cleared Conavi's next-gen hybrid IVUS‑OCT system
• Awards include MedTech Breakthrough and TAG Innovation recognitions
• U.S. commercial launch targeted for H2 2026 after scale‑up
• Proposed public offering aims to fund U.S. rollout and working capital
• Cash on hand ~US$3.33 million, down from prior quarter

Pulse Analysis

Hybrid intravascular imaging that combines IVUS and OCT is poised to become a cornerstone of modern percutaneous coronary interventions. By delivering simultaneous, co‑registered images, the technology shortens procedure time, improves lesion assessment, and reduces contrast use—benefits that align with hospitals’ cost‑containment goals and physicians’ demand for precision. As the market for image‑guided PCI expands, vendors that can offer an integrated platform gain a competitive edge over single‑modality systems.

Conavi’s FDA 510(k) clearance marks a regulatory milestone that unlocks the U.S. market, a region accounting for the majority of global cardiovascular device spend. The company’s recent MedTech Breakthrough and TAG Innovation awards provide third‑party validation, bolstering credibility with clinicians and investors alike. Concurrently, Conavi is executing a commercial‑readiness program that includes manufacturing scale‑up, reliability testing, and physician training, all aimed at a targeted H2 2026 launch. To finance these activities, the firm announced a public offering of shares and pre‑funded warrants, signaling confidence in its capital strategy.

Financially, Conavi remains in a development phase, reporting six‑month revenue of CAD 0.3 million (≈US$0.22 million) and a net loss of CAD 7.5 million (≈US$5.55 million). Cash balances of CAD 4.5 million (≈US$3.33 million) provide a runway for near‑term commercialization but underscore the need for additional funding. Investors will watch the upcoming public offering and the execution of the U.S. rollout, as successful market entry could transform Conavi from a niche innovator into a significant player in the intravascular imaging space.